apocell Home Contact Us
  • CLINICAL TRIAL EXPERIENCE
    SPECIMENS ANALYZED
  • proposal request contact us
  • News

    February 4, 2010

    ApoCell Awarded Contract to Develop Circulating Tumor Cell Isolation Technology (ApoStreamTM) from NCI's Division of Cancer Treatment and Diagnosis (DCTD)

    June 1, 2011, Houston

    ApoCell Launches Revolutionary Circulating Cancer Cell Detection System - ApoStreamTM

    August 10, 2011, Houston

    ApoCell Awarded $2.9M from SAIC-Frederick, Inc. to Deliver a New Platform for Detection and Molecular Analysis of Circulating Tumor Cells

    August 24, 2011, Houston

    ApoCell named to Inc Magazine's List of the 5000 Fastest Growing Private Companies

    September 23, 2011, Houston

    ApoCell named to Houston Business Journal's List of the 100 Fastest-Growing Private Companies in Houston

    September 30, 2011, Houston

    ApoCell awarded SBIR Grant to Develop Point of Care Device for Antibody Independent Isolation of Circulating Tumor Cells

Translating every cell’s story.

ApoCell’s CTC molecular profiling services detect the genetic and molecular changes unique to each patient. Our scientists simultaneously characterize Circulating Tumor Cells (CTCs) or Circulating Endothelial Cells (CECs) for single nucleotide polymorphisms (SNPs), gene translocations, rearrangements, copy number alterations, and changes in mRNA or microRNA expression.

Genomic Analysis

Gene Expression Profiling

  • RNA isolation from Circulating Tumor Cells (CTCs), Circulating Endothelial Cells (CECs), or Peripheral Blood Mononuclear Cells (PBMCs)
  • RNA quality control using Agilent BioAnalyzer®
  • Single cell RNA isolation, end-point RT-PCR, quantitative RT-PCR
  • Gene expression assays using TaqMan® quantitative RT-PCR
  • Gene expression assays using SYBR-Green quantitative RT-PCR
  • Gene expression profiling using TaqMan® Custom and Gene Signature Array Microfluidic Cards and Plates
  • Illumina Human HT-12 Expression BeadChip Arrays
  •  

    Cytogenetic Abnormalities (FISH)

  • Custom Fluorescence In Situ Hybridization (FISH) in CTCs, CECs, FFPE, bone, or frozen tissue
  • Vysis® FISH assays in CTCs, CECs, FFPE, bone, or frozen tissue
  • PathVysionâ„¢ for accessing gene amplification in breast cancer
  • UroVysionâ„¢ aids in the diagnosis and monitoring recurrence in bladder cancer
  •  

    Mutation Profiling

  • Isolation of genomic DNA from Circulating Tumor Cells (CTCs), Circulating Endothelial Cells (CECs), Peripheral Blood Mononuclear Cells (PBMCs), plasma, serum, FFPE, or frozen tissue
  • PCR amplification and DNA Sequencing
  • Sequenom® SNP Genotyping
  • TaqMan® SNP Genotyping
  • DxS® (Qiagen) Mutation Assays (EGFR29, KRAS, BRAF, BCR-ABL, PI3K)
  • Custom Allele-Specific PCR for SNP detection
  • Â